All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
EquityEquity IPOs

Circassia successfully imports biotech frenzy to UK investors

drugs are bad, mmmk? (right size)

Circassia, a UK biotech firm that is developing drugs to combat cat allergies, raised £210m through an IPO that brought the busy US sector to UK investors.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree